Titre :

Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TC.

Auteur(s) :

Caulier, Alexis [Auteur]
Drumez, Elodie [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Gauthier, Jordan [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Robin, Marie [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Blaise, Didier [Auteur]
Beguin, Yves [Auteur]
Michallet, Mauricette [Auteur]
Chevallier, Patrice [Auteur]
Bay, Jacques-Olivier [Auteur]
Vigouroux, Stephane [Auteur]
Desbrosses, Yohan [Auteur]
Cornillon, Jerome [Auteur]
Nguyen, Stephanie [Auteur]
Dauriac, Charles [Auteur]
Peffault De Latour, Regis [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Lioure, Bruno [Auteur]
Rohrlich, Pierre-Simon [Auteur]
Carre, Martin [Auteur]
Bourhis, Jean-Henri [Auteur]
Huynh, Anne [Auteur]
Suarez, Felipe [Auteur]
Garnier, Federico [Auteur]
Duhamel, Alain [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]

Titre de la revue :

Current Research in Translational Medicine

Nom court de la revue :

Curr. Res. Transl. Med.

Numéro :

67

Pagination :

8-15

Date de publication :

2019-02

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

PURPOSE: We developed a prognostic scoring system to evaluate the prognosis of myelodysplastic syndrome (MDS) patients surviving more than 100 days allogeneic hematopoietic cell transplantation after (allo-HCT). PATIENTS ...
Lire la suite >PURPOSE: We developed a prognostic scoring system to evaluate the prognosis of myelodysplastic syndrome (MDS) patients surviving more than 100 days allogeneic hematopoietic cell transplantation after (allo-HCT). PATIENTS AND METHODS: We performed a landmark analysis on a derivation cohort of 393 cases to identify prognostic factors for 3-year overall survival. Potential predictor variables included demographic and clinical data, transplantation modalities and early post-transplant complications. The scoring system was tested against a validation cohort which included 391 patients. RESULTS: Complications occurring before day 100 such as relapse [HR = 6.7; 95%CI, 4.5-10.0] (4 points), lack of platelet recovery [HR, 3.6; 95%CI, 2.2-5.8] (2 points), grade-II acute GVHD [HR = 1.7; 95%CI, 1.2-2.5] (1 point) and grade-III/IV [HR = 2.6; 95%CI, 1.8 -3.8] (2 points) were the only independent predictors of 3-year OS. The 3-year OS associated with low (0), intermediate (1-3) and high (>/=4) risk scores was respectively 70%, 46% and 6%. The model performed consistently in both cohorts, with good calibration. CONCLUSION: This post-transplant scoring system is a powerful predictor of outcome after allo-HCT for MDS, and can provide useful guidance for clinicians. Additional studies are required to evaluate this scoring system for other hematologic malignancies.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Inserm
Université de Lille
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Équipe(s) de recherche :

Immunity, inflammation and fibrsis in auto and allo-reactivity

Date de dépôt :

2019-03-01T14:07:58Z
2021-05-17T06:48:52Z
2024-01-16T08:42:40Z